Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.24+0.03 (+11.89%)
Close on Nov 18, 2026Market cap $568.73KP/E –Yield –
Lakewood-Amedex Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
No free cash flow figures for Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?